Setara Biosciences, a clinical-stage rare disease biotech formed by Actio Biosciences alums, is launching with $90 million raised, the company said Friday.
Why it matters: The financing gives part of Actio's drug portfolio a new path forward after the company's $1.32 billion sale to Jazz Pharmaceuticals.
